Lefamulin
Xenleta (lefamulin) is a small molecule pharmaceutical. Lefamulin was first approved as Xenleta on 2019-08-19. It is used to treat bacterial pneumonia in the USA. It has been approved in Europe to treat bacterial pneumonia and community-acquired infections. Xenleta's patents are valid until 2031-05-23 (FDA).
| Trade Name | Xenleta |
|---|---|
| Common Name | Lefamulin |
| Indication | bacterial pneumonia, community-acquired infections |
| Drug Class | Antibacterials, pleuromulin derivatives |
